Cochrane Review Group
Neonatal
210 systematic reviews in Neonatal ask 2,353 questions. 18.4% have no studies to answer them, 25.9% rest on very low certainty evidence and 20.3% reach moderate or high certainty.
Reviews
210
Questions
2,353
current versions
No studies
18.4%
Moderate or high
20.3%
No studies 432 · 18.4%Ungraded 99 · 4.2%Very low 609 · 25.9%Low 737 · 31.3%Moderate 385 · 16.4%High 91 · 3.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Salbutamol vs placebo Adverse effects of bronchodilators, including hypokalaemia, tachycardia, cardiac arrhythmia, tremor, hypertension and hyperglycaemia ‐ not reported · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Salbutamol vs placebo Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | 1 study · 173 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Pulmonary air leak, any (during first hospitalisation) Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Bronchopulmonary dysplasia (clinical definition) among survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 0.17 [0.01, 3.37] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 210
Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
CochraneSoF table
4 questions
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
CochraneSoF table
18 questions
Oral dextrose gel for the treatment of hypoglycaemia in newborn infants
CochraneSoF table
6 questions
Periodic change of body position under phototherapy in term and preterm neonates with hyperbilirubinaemia
CochraneSoF table
5 questions
Cuffed versus uncuffed endotracheal tubes for neonates
CochraneSoF table
7 questions
Synbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
CochraneSoF table
4 questions
Masks versus prongs as interfaces for nasal continuous positive airway pressure in preterm infants
CochraneSoF table
6 questions
Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
CochraneSoF table
5 questions
Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
CochraneSoF table
6 questions
Topical emollient for preventing infection in preterm infants
CochraneSoF table
8 questions
Slow advancement of enteral feed volumes to prevent necrotising enterocolitis in very low birth weight infants
CochraneSoF table
4 questions
Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants
CochraneSoF table
21 questions
Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams
CochraneSoF table
7 questions
Sedatives for opioid withdrawal in newborn infants
CochraneSoF table
42 questions
Opioid treatment for opioid withdrawal in newborn infants
CochraneSoF table
56 questions
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
CochraneSoF table
9 questions
Push versus gravity for intermittent bolus gavage tube feeding of preterm and low birth weight infants
CochraneSoF table
6 questions
Avoidance of bottles during the establishment of breastfeeds in preterm infants
CochraneSoF table
4 questions
Lung recruitment manoeuvres for reducing mortality and respiratory morbidity in mechanically ventilated neonates
CochraneSoF table
7 questions
Fluid restriction in the management of transient tachypnea of the newborn
CochraneSoF table
7 questions
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome
CochraneSoF table
7 questions
Salbutamol for transient tachypnea of the newborn
CochraneSoF table
7 questions
Short versus long feeding interval for bolus feedings in very preterm infants
CochraneSoF table
5 questions
High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants
CochraneSoF table
10 questions
Tracheal suction at birth in non‐vigorous neonates born through meconium‐stained amniotic fluid
CochraneSoF table
8 questions